Tesamorelin is the most clinically studied of the three
Our team responds to all questions and concerns, providing a safe environment for your transformation
Contact Us Our customer representative team is available 7 days a week from 9 am - 9 pm
Piuri G, Zocchi M, Della Porta M, Ficara V, Manoni M, Zuccotti GV, et al
In the SURPASS-3 trial, which compared tirzepatide to insulin degludec in patients already taking metformin with or without an SGLT2 inhibitor, hypoglycemia rates remained relatively low with tirzepatide
For dual agonists: because they are stronger, the sideeffect profile may be similar or somewhat amplified